Novo Nordisk ... trial, and in phase 1b testing showed an encouraging safety profile, as well as early signs of functional cardiac benefits, including a reduction in the heart failure biomarker ...

LONDON/COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

Kevin Mohatt / The Washington Post / Getty Images Novo Nordisk's U.S.-listed shares tumbled over 19% Friday morning after it released data from a new weight loss drug trial. The new drug ...

Novo Nordisk (NYSE ... than what Eli Lilly's Zepbound accomplished in a similar trial. The market reacted the way it did because Novo Nordisk's management had promised a 25% average weight ...

Novo Nordisk has announced its latest trial result for the new obesity drug, CagriSema, which disappointed investors and sent its share price plunging 20% in Denmark on Friday, the sharpest one ...

COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it ...

LONDON/COPENHAGEN (Reuters) -Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion ...

Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

He said Novo Nordisk would use insights from the trial “to further explore the additional weight loss potential of CagriSema.” Novo Nordisk’s stock fell about 19% in early Friday trading on ...

Shares in Novo Nordisk plunged 20% on Friday. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and ...